Application of Immune Checkpoint Inhibitors in Common Gynecological Malignancies

Gynecological malignant tumors threaten women’s lives and property, among which cervical cancer, endometrial cancer, ovarian cancer and other malignancies have a high incidence rate and mortality trend with the change of women’s lifestyle and the aggravation of their psychological load in recent years. Therefore, standardized and efficient treatment of gynecological malignancies is crucial for maintaining long-term survival and a happy life for female patients. At present, immunotherapy has turn into the fourth cancer therapeutic tool after traditional operation, chemotherapy, and radiation therapy. In recent years, with the increasing attention to immunotherapy for gynecological tumors, immune checkpoint inhibitors is widely used in clinical practice of gynecological tumors in China, and their clinical efficacy is outstanding. This article summarizes clinical use and occurrence of adverse events of immune checkpoint inhibitors in gynecological tumors in recent years, and explores the therapeutic prospects of immune inhibitors in gynecological tumor diseases, in order to promote the development and innovation of tumor immunotherapy in the future.